• ACVC Callout
News
ICViewExpert PerspectivesMedical World NewsVideosWebinars
Conference
Infection Control TodaySupplements And Featured Publications
CME/CEJob BoardPartnersSponsoredWhitepapers
Print SubscriptioneNewsletter
Educator of the Year Nomination FormEducator of the Year Official RulesEducator of the Year
Advanced Technology
Bug of the Month
COVID-19
Environmental Services
HAIs
Hand Hygiene
Long-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Prevention
Sterile Processing
Surface Disinfection
Vascular Access
Spotlight -
  • Expert Perspectives on Personal Protection Guidelines and Standardization Practices
  • Bug of the Month
Advanced Technology
Bug of the Month
COVID-19
Environmental Services
HAIs
Hand Hygiene
Long-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Prevention
Sterile Processing
Surface Disinfection
Vascular Access
    • News
    • Conference
Advertisement

One-Third of Children Up to Age 3 Exposed to Zika In-Utero Have Neurological Problems

July 10, 2019
Article

New UCLA-led research suggests that 32 percent of children up to the age of 3 years who were exposed to the Zika virus during the mother’s pregnancy had below-average neurological development.

The study also found that fewer than 4 percent of 216 children evaluated had microcephaly -a smaller-than-normal head that is one of the hallmarks of the mosquito-borne disease. The heads of two of those children grew to normal size over time, the researchers reported.

The study was published in the journal Nature Medicine.

The findings, conducted by UCLA researchers with colleagues in Rio de Janeiro, Brazil, where the disease was first detected, as well as in Austria and Germany, are a follow-up to previous research. That study showed substantial neurologic damage identified through developmental testing and neuroimaging in children younger than age 2 whose mothers were infected with Zika during their pregnancies.

“Children who were exposed to Zika during their mothers’ pregnancy need to have developmental assessments over time, and eye and hearing exams should be performed,” said the study’s lead author, Dr. Karin Nielsen-Saines, a professor of clinical pediatrics in the division of pediatric infectious diseases at the David Geffen School of Medicine at UCLA and at UCLA Mattel Children’s Hospital. “If there is risk of developmental delay, or developmental delay is identified, there are cognitive, language and behavior interventions that can be put in place to improve outcomes for these children.”

The researchers tested 146 children using the Bayley-III test, an extended neurodevelopmental assessment that checks language, cognitive and motor development. They used the Hammersmith Infant Neurologic Evaluation, or HINE, a less detailed assessment, on the 70 other children whose parents did not wish to take their children in for the lengthy Bayley-III.

The researchers found that in the Bayley-III group, 51 children tested for language, 14   tested for cognitive development, and 24 evaluated for motor development scored below average.

Of the HINE group, three children had abnormal results and 67 showed normal results.

In addition, 10 of 137 children who had eye exams showed abnormal results and 14 of 114 children who underwent auditory checks had hearing deficits.

Two children in the study had normal head measurements at birth, but developed microcephaly during their first year, while two others with microcephaly at the time of birth went on to develop normal head circumference by age 1.

“This means that microcephaly is not necessarily static,” Nielsen-Saines said.

The researchers did not have a comparison group of non-Zika-exposed children born at the same time and raised in the same environment as those known to have been exposed to Zika in-utero.

“Zika exposure can be a very difficult condition to diagnose in retrospect, so we can’t rule out undiagnosed Zika infection in a control group of children enrolled at the same time,” Nielsen-Saines said. “Neurodevelopmental tests should be done simultaneously in similar populations with the same background.”

Nielsen-Saines noted that proper long-term follow-up of children whose mothers had Zika infection in pregnancy is necessary.

“These children require close attention and ongoing surveillance, so that prompt interventions to improve their development can be provided if needed,” she said.

Study co-authors are Tara Kerin, Dr. Irena Tsui, Dr. Kristina Adachi, Dr. James Cherry, and Genhong Cheng, all of UCLA; and other researchers from California, Austria, Brazil and Germany. The journal article contains the full list.

The study was funded by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, the National Eye Institute, the Thrasher Research Fund, the Bill and Melinda Gates Foundation, the United Kingdom’s Department for International Development, ZikaPlan (Preparedness Latin American Network) and other sources in Brazil and France.

Source: University of California, Los Angeles (UCLA)


 

Related Videos
Set of white bottles with cleaning liquids on the white background. (Adobe Stock 6338071172112 by zolnierek)
Medical investigators going over data. (AdobeStock 589197902 by Wasan)
CDC logo is seen on a laptop. (Adobe Stock 428450603 by monticellllo)
Association for the Health Care Environment (Logo used with permission)
COVID-19 germs, fungi, bacteria objects. (Adobe Stock 584704860 by chawalit)
Ambassador Deborah Birx, , speaks with Infection Control Today about masks in schools and the newest variant.
mRNA technology  (Adobe Stock 485886181 by kaptn)
Ambassador Deborah Birx, MD
Woman lying in hospital bed (Adobe Stock, unknown)
Related Content

Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns

September 28th 2023

Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants

September 27th 2023

I’m Not Just an Infection Preventionist

September 26th 2023

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023

Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns

September 28th 2023

Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants

September 27th 2023

I’m Not Just an Infection Preventionist

September 26th 2023

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023

Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns

September 28th 2023

Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants

September 27th 2023

I’m Not Just an Infection Preventionist

September 26th 2023

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023
Related Content
Advertisement

In this photo illustration, National Foundation for Infectious Diseases logo is seen displayed on a smartphone    (Adobe Stock 346303670 By Игорь Головнёв)

Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns

September 28th 2023
Article

Cases of COVID-19, RSV, and influenza are expected to rise this fall and winter season; yet, the number of people who plan on getting the vaccines for each of the infections remains low, according to the NFID announcement today.


COVID-19 germs, fungi, bacteria objects.   (Adobe Stock 584704860 by chawalit)

Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants

September 27th 2023
Article

As COVID-19 restrictions eased up, other respiratory viruses began circulating alongside SARS-CoV-2. It's crucial to identify cases and understand the symptoms of these infections to track the evolution of the virus and what health care workers should look out for.


An infection preventionist taking off her mask. (Adobe Stock, unknown)

I’m Not Just an Infection Preventionist

September 26th 2023
Article

Infection preventionists (IP) can come from many different backgrounds. This is 1 opinion from 1 very successful IP who doesn't have an RN or a BSN and the bullying that sometimes occurs.


(Adobe Stock FILE #:  56169337 by thinglass)

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023
Article

Many infection preventionists (IPs) disagree on the minimum requirement to have the IP position. Let Infection Control Today know your opinion. Answer this poll, and send your thoughts to Senior Editor Tori Whitacre Martonicz at tmartonicz@mjhlifesciences.com.


Influenza, RSV, and COVID-19 (AdobeStock_249346161, AdobeStock_538653843,AdobeStock_471755796)

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023
Article

The interaction between the respiratory viruses SARS-CoV-2, influenza, and RSV, poses ongoing challenges. Personal protective measures, testing, and vaccination are critical components of our strategy to mitigate the impact of these viruses.


weekly rounds with infection control today

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023
Article

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending September 24, 2023.

Advertise
About Us
Editorial Board
Contact Us
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News